Drugs / Monosialotetrahexose ganglioside sodium
Monosialotetrahexose ganglioside sodium
also known as
Monosialate Tetrahexose-ganglioside Sodium Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05802342 | Apr 2023 → Dec 2024 | — | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monosialotetrahexose ganglioside sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05802342 ↗ |
| Known as | Monosialate Tetrahexose-ganglioside Sodium Injection | “Monosialate Tetrahexose-ganglioside Sodium Injection (GM1)” NCT05802342 ↗ |